Onyx seeks expedited FDA review of myeloma drug carfilzomib

09/28/2011 | Xconomy

Onyx Pharmaceuticals has asked the FDA for priority evaluation of carfilzomib, a treatment candidate for multiple myeloma. Clinical data show that the drug reduces tumor size in patients who have received at least two previous therapies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ